Contact PR

To use this feature, join Babbler easily !

arrow_back

Babbler is a free tool for journalists
Do not suffer news anymore, control it


By signing up you will be able to contact hundreds of press officer :
Caroline Grangie
Leboncoin
Media relation manager
Manon Guignard
Uber
Communication Associate
Sheherazade Renoux
PMU
Communication Manager

To learn more, watch the video

You're 1 click away from signing up
What is Babbler!

Previous

Nice to see you again !

Press release

FDA to review Zynquista as potential treatment for type 1 diabetes
timer minutes reading time minute reading time

Copy link
Bridgewater, NJ and The Woodlands, TX – May 22, 2018 – The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type
fda-to-review-zynquista-as-potential-treatment-for-type-1-diabetes-1

Click to get original image size

“If approved, Zynquista would be the first oral antidiabetic drug approved in the U.S. for use by adults with type 1 diabetes, in combination with insulin.” says Jorge Insuasty, Senior-Vice President, Global Head of Development, Sanofi.

“We look forward to working with the FDA through the review process with a view towards bringing this investigational medicine to adults with type 1 diabetes in the U.S.” Developed in partnership with Lexicon Pharmaceuticals, Inc., Zynquista is an investigational oral dual inhibitor of SGLT-1 and SGLT-2, proteins that influence how the intestines and kidneys absorb and eliminate sugar (glucose) resulting in improved glucose control and additional clinical benefits.

“After decades of little change and innovation, the treatment of type 1 diabetes has begun to shift significantly and, if approved, our dual SGLT1 and SGLT2 inhibitor, Zynquista, would be the first approved oral therapy used in combination with insulin to improve glycemic control and patient outcomes for adults in the United States who are living with type 1 diabetes,” said Pablo Lapuerta, M.D., executive vice president and chief medical officer, Lexicon.

“The acceptance of the NDA filing moves us closer to providing a meaningful option for people with type 1 diabetes and we look forward to continuing to work closely with the FDA during the review process.” The FDA New Drug Application for sotagliflozin is based on data from the inTandem clinical trial program which includes three Phase 3 clinical trials assessing the safety and efficacy of Zynquista in approximately 3,000 adults with inadequately controlled type 1 diabetes.1–3 The safety and efficacy data have not yet been evaluated by any regulatory authority.

  • Health & Medicine
  • Medicine
  • Men's Health
  • Women's Health
inscrit avec succès

Congratulations, you're registered on Babbler!

Discover now all the news waiting for you on Babbler: visit your newsfeed.!

Your topics have been selected, you can change it by clicking here

  • Health & Medicine
  • Medicine
  • Men's Health